KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Notes Payables (2016 - 2026)

Gsk has reported Notes Payables over the past 18 years, most recently at -$327.6 million for Q1 2026.

  • For Q1 2026, Notes Payables fell 22.12% year-over-year to -$327.6 million; the TTM value through Mar 2026 reached -$327.6 million, down 22.12%, while the annual FY2025 figure was -$4.0 billion, 232.89% down from the prior year.
  • Notes Payables for Q1 2026 was -$327.6 million at Gsk, up from -$4.0 billion in the prior quarter.
  • Over five years, Notes Payables peaked at $4.6 billion in Q4 2022 and troughed at -$7.4 billion in Q2 2023.
  • A 5-year average of -$1.2 billion and a median of -$289.8 million in 2022 define the central range for Notes Payables.
  • Biggest five-year swings in Notes Payables: soared 93.96% in 2023 and later tumbled 1708.56% in 2025.
  • Year by year, Notes Payables stood at $4.6 billion in 2022, then decreased by 24.68% to $3.5 billion in 2023, then decreased by 13.65% to $3.0 billion in 2024, then crashed by 232.89% to -$4.0 billion in 2025, then soared by 91.82% to -$327.6 million in 2026.
  • Business Quant data shows Notes Payables for GSK at -$327.6 million in Q1 2026, -$4.0 billion in Q4 2025, and -$3.9 billion in Q3 2025.